The LAM Foundation 2026 Grant Program — Pilot-Feasibility, Clinical Research, and Patient Quality of Life Awards

About this program

The LAM Foundation’s 2026 grant program funds innovative scientific and clinical research on lymphangioleiomyomatosis (LAM), with priority areas including discovery or repurposing of therapies (including combinations with mTOR inhibitors), new therapeutic targets, sex as a biological variable, and projects that improve patient quality of life. In-cycle mechanisms are Pilot‑Feasibility Research Awards (up to $50,000/1 year) for hypothesis‑generating or -testing work with preliminary data, Clinical Research Awards (up to $50,000/1 year) for human‑subjects‑based, patient‑centered clinical studies feasible within one year, and Patient Quality of Life Awards (up to $25,000/1 year) for rigorous studies that must include patient input and demonstrate real‑world outcomes. Applicants must submit a required Letter of Intent via ProposalCentral (one LOI per laboratory or research group) and complete all application steps through ProposalCentral; awards should be feasible within the funding period and positioned to lead to larger funding or tangible clinical advances. For application details and inquiries, applicants should follow the Foundation’s Request for Applications and contact the Grant Coordinator at research@thelamfoundation.org.